|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Automatic computetized radiographic identification of cephalometric landmarks显示文摘 | Rodolph D J Sinclair P M Coggins J M | 1998 | American Journal of Orthodontics and Dentofacial Orthopaedics1998，113，： | 1 |
| 2 | Effects of sleeve gastrectomy in high fat diet-induced obese mice: respective role of reduced caloric intake, white adipose tissue inflammation and changes in adipose tissue and ectopic fat depots显示文摘 | Anne-Sophie Schneck Antonio Iannelli Stéphanie Patouraux Déborah Rousseau Stéphanie Bonnafous Beatrice Bailly-Maitre Ophélia Thuc Carole Rovere Patricia Panaia-Ferrari Rodolphe Anty Albert Tran Philippe Gual Jean Gugenheim | 2014 | Surgical Endoscopy2014，，2： | 1 |
| 3 | Identification of Adipose Tissue Dendritic Cells Correlated With Obesity-Associated Insulin-Resistance and Inducing Th17 Responses in Mice and Patients显示文摘 | Adeline Bertola Thomas Ciucci Déborah Rousseau Virginie Bourlier Carine Duffaut Stéphanie Bonnafous Claudine Blin-Wakkach Rodolphe Anty Antonio Iannelli Jean Gugenheim Albert Tran Anne Bouloumié Philippe Gual Abdelilah Wakkach | 2012 | Diabetes2012，，9： | 1 |
| 4 | Experimenting with quantitative evaluation tools for monitoring operational security显示文摘 | Rodolphe O Yves D and Mohamed K | 1999 | IEEE Transactions on Software Engineering1999，25，5： | 1 |
| 5 | in vitro determination of the allergenic potential of technologically altered hen's egg显示文摘 | SABINE H HARTMUT D K RODOLPHE | | 0，，05： | 1 |
| 6 | Evo- lutionary algorithms for constrained parameter optimiza- tion problems显示文摘 | Michalewicz Z Rodolphe D D Schoenauer M | 1996 | Evolutionary Computation1996，4，： | 1 |
| 7 | Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: A randomized controlled trial显示文摘 | Jean Marc Perarnau Amélie Le Gouge Charlotte Nicolas Louis d’Alteroche Patrick Borentain Faouzi Saliba Anne Minello Rodolphe Anty Carine Chagneau-Derrode Pierre Henri Bernard Armand Abergel Isabelle Ollivier-Hourmand Jérome Gournay Jean Ayoub Christophe G | 2014 | Journal of Hepatology2014，，： | 1 |
| 8 | Evolutionary algorithms for constrained engineering problems显示文摘 | Michalewicz Z Dasgupta D Rodolphe G R Schoenauer M | 1996 | Computers and Industrial Engineering1996，30，4： | 1 |
| 9 | Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence显示文摘AIM: To identify risk factors associated with survival in patients retransplanted for hepatitis C virus(HCV) recurrence and to apply a survival score to this population.METHODS: We retrospectively identified 108 patients retransplanted for HCV recurrence in eight European liver transplantation centers(seven in France, one in Spain). Data collection comprised clinical and laboratory variables, including virological and antiviral treatment data. We then analyzed the factors associated with survival in this population. A recently published score that predicts survival in retransplantation in patients with hepatitis C was applied. Because there are currently no uniform recommendations regarding selection of the best candidates for retransplantation in this setting, we also described the clinical characteristics of 164 patients not retransplanted, with F3, F4, or fibrosing cholestatic hepatitis(FCH) post-first graft presenting with hepatic decompensation. RESULTS: Overall retransplantation patient survival rates were 55%, 47%, and 43% at 3, 5, and 10 years, respectively. Patients who were retransplanted for advanced cirrhosis had survival rates of 59%, 52%, and 49% at 3, 5, and 10 years, while those retransplanted for FCH had survival rates of 34%, 29%, and 11%, respectively. Under multivariate analysis, and adjusting for the center effect and the occurrence of FCH, factors associated with better survival after retransplantation were: negative HCV viremia before retransplantation, antiviral therapy after retransplantation, non-genotype 1, a Model for End-stage Liver Disease(MELD) score < 25 when replaced on the waiting list, and a retransplantation donor age < 60 years. Although the numbers were small, in the context of the new antivirals era, we showed that outcomes in patientswho underwent retransplantation with undetectable HCV viremia did not depend on donor age and MELD score. The Andrés score was applied to 102 patients for whom all score variables were available, producing a mean score of 43.4(SD = 6.6). Survival rates after the date of the first decompensation post-first liver transplantation(LT1) in the liver retransplantation(re LT) group(94 patients decompensated) at 3, 5, and 10 years were 62%, 59%, and 51%, respectively, among 78 retransplanted individuals with advanced cirrhosis, and 42%, 32%, and 16% among 16 retransplanted individuals with FCH. In the non-re LT group with hepatic decompensation, survival rates were 27%, 18%, and 9% at 3, 5, and 10 years, respectively(P < 0.0001). Compared with non-retransplanted patients, retransplanted patients were younger at LT1(mean age 48 ± 8 years compared to 53 ± 9 years in the no re LT group, P < 0.0001), less likely to have human immunodeficiency virus(HIV) co-infection(4% vs 14% among no re LT patients, P = 0.005), more likely to have received corticosteroid bolus therapy after LT1(25% in re LT vs 12% in the no re LT group, P = 0.01), and more likely to have presented with sustained virological response(SVR) after the first transplantation(20% in the re LT group vs 7% in the no re LT group, P = 0.028).CONCLUSION: Antiviral therapy before and after retransplantation had a substantial impact on survival in the context of retransplantation for HCV recurrence, and with the new direct-acting antivirals now available, outcomes should be even better in the future. | Alice Tung Wan Song Rodolphe Sobesky Carmen Vinaixa Jérome Dumortier Sylvie Radenne Francois Durand Yvon Calmus Géraldine Rousseau Marianne Latournerie Cyrille Feray Valérie Delvart Bruno Roche Stéphanie Haim-Boukobza Anne-Marie Roque-Afonso Denis Castaing Edson Abdala Luiz Augusto Carneiro D’Albuquerque Jean-Charles Duclos-Vallée Marina Berenguer Didier Samuel | 2016 | World Journal of Gastroenterology2016，22，18： | 1 |
| 10 | CRISPR provides acquired resistance against viruses in prokaryotes显示文摘 | RODOLPHE B CHRISTOPHE F HELENE D | 2007 | Science2007，315，： | 1 |
| 11 | Biliary differentiation and bile duct morphogenesis in development and disease显示文摘 | Peggy Raynaud Rodolphe Carpentier Aline Antoniou Frédéric P. Lemaigre | 2009 | International Journal of Biochemistry and Cell Biology2009，，2： | 1 |
| 12 | Rapid detection of HIV-1 by reverse-transcription,loop-mediated iso- thermal amplification(RT-LAMP) 显示文摘 | Curtis K A Rodolph D L Owen S M | 2008 | J Virol Meth- ods2008，2，： | 1 |
| 13 | Holographic diffraction grating显示文摘 | SCHMAHL G RODOLPH D | 1976 | Progress in Optics1976，14，： | 1 |
| 14 | 232 *2H2O:A new high Tc cyano-bridged ferrimagnet based on the4-building block and induced by counterion exchange显示文摘 | Joulia L Rodolphe C Bruno D | 2002 | European Journal of Chemistry2002，12，8： | 1 |
| 15 | A finite element model of apical force distribution from orthodontic tooth movement 显示文摘 | RODOLPH D J WILLES P M SAMESHINA G T | 2001 | Angle Orthod2001，71，2： | 1 |
| 16 | Evolutionary algorithms for constrained engineering problems显示文摘 | MICHALEWICZ Z DASGUPTA D RODOLPHE G | 1996 | Computers and Industry Engineer1996，30，4： | 1 |
| 17 | Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma:Real-life Data on Liver Disease,Treatment and Prognosis显示文摘Background and Aims:Hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma(iCCA)have common features and differences.This real-life study investigated their characteristics,treatment modalities,and prognoses.Methods:This retrospective comparative study was performed in 1,075 patients seen at one tertiary center between January 2008 and December 2020.Overall survival(OS)was estimated by the Kaplan-Meier method.Subclassification of iCCAs after histological and radiological review,and molecular profiling was performed.Results:HCCs patients were more likely to have early-stage disease than iCCA patients.iCCA patients were more likely to be female,especially those patients without cirrhosis(43%vs.17%).Cirrhosis was prominent among HCC patients(89%vs.34%),but no difference in underlying liver disease among cirrhotic patients was found.OS of HCC patients was 18.4(95%CI:6.4,48.3)months,that of iCCA patients was 7.0(95%CI:3.4,20.1)months.OS of Barcelona Clinic Liver Cancer C HCC patients was 7.8(95%CI:4.3,14.2)months,that of advanced/metastatic iCCA patients was 8.5(95%CI:5.7,12.3)months.In patients treated with sorafenib,OS was longer in HCC patients who received subsequent tyrosine kinase inhibitor therapies.No significant OS difference was found between iCCA patients with and without cirrhosis or according to histological subtype.A targetable molecular alteration was detected in 50%of the iCCA patients.Conclusions:In this French series,cirrhosis was common in iCCA,which showed etiological factors comparable to those of HCC,implying a distinct oncogenic pathway.Both entities had a dismal prognosis at advanced stages.However,systemic therapies sequencing in HCC and molecular profiling in iCCA offer new insights. | Xavier Adhoute Olivia Pietri Guillaume Pénaranda Thomas Wolf Patrick Beaurain Olivier Monnet Arthur Laquière Justine Bonomini Frédéric Neumann Olivier Levrel Jean-Pascal Buono Xavier Hanna Paul Castellani HervéPerrier Marc Bourliere Rodolphe Anty | 2023 | Journal of Clinical and Translational Hepatology2023，11，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员